Orum Therapeutics

Cell-Penetrating Antibodies

ORM-1023 RD SCLC; 3 additional programs RD undisclosed

Orum Therapeutics is pioneering the development of antibody-enabled, targeted protein degraders for cancer therapeutics. Antibody-based biologics, by having specificity for cancer antigens, have a lot of therapeutic potential. Orum’s approach is to develop their proprietary Dual-precision Targeted Protein Degradation (TPD2) method that exploits the specificity of antibodies by tagging them with targeted protein degrader payloads. While TPDs, typically small molecules, indiscriminately enter many cells throughout the body, covalent attachment to antibodies drives localization to specific cells (TPD2). Due to the versatility of their platform, Orum is creating a multiplatform pipeline to cover various cancer indications.